Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 Expectations
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results topping the market's revenue expectations , with sales up 22.7% year on year to $177.8 million. The company expects the full year's revenue to be around $742.5 million, close to analysts' estimates. Its non-GAAP profit of $1.49 per share was 2.8% above analysts' consensus estimates.
Is now the time to buy Collegium Pharmaceutical? Find out in our full research report.
Revenue: $177.8 million vs analyst estimates of $172.8 million (22.7% year-on-year growth, 2.9% beat)
Adjusted EPS: $1.49 vs analyst estimates of $1.45 (2.8% beat)
Adjusted EBITDA: $95.15 million vs analyst estimates of $96.5 million (53.5% margin, 1.4% miss)
The company reconfirmed its revenue guidance for the full year of $742.5 million at the midpoint
EBITDA guidance for the full year is $442.5 million at the midpoint, above analyst estimates of $438.5 million
Operating Margin: 12.2%, down from 34.1% in the same quarter last year
Market Capitalization: $869.2 million
'Collegium is off to a strong start in 2025. We have made significant progress towards our key strategic priorities including growing Jornay PM, maximizing our pain portfolio, and strategically deploying capital to further enhance shareholder value,' said Vikram Karnani, President and Chief Executive Officer.
Pioneering abuse-deterrent technology in a field plagued by addiction concerns, Collegium Pharmaceutical (NASDAQ:COLL) develops and markets specialty medications for treating moderate to severe pain, including abuse-deterrent opioid formulations.
Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Collegium Pharmaceutical grew its sales at an impressive 17.3% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Collegium Pharmaceutical's annualized revenue growth of 12.5% over the last two years is below its five-year trend, but we still think the results suggest healthy demand.
This quarter, Collegium Pharmaceutical reported robust year-on-year revenue growth of 22.7%, and its $177.8 million of revenue topped Wall Street estimates by 2.9%.
Looking ahead, sell-side analysts expect revenue to grow 13.2% over the next 12 months, similar to its two-year rate. This projection is admirable and suggests the market sees success for its products and services.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D.
Collegium Pharmaceutical has managed its cost base well over the last five years. It demonstrated solid profitability for a healthcare business, producing an average operating margin of 19.6%.
Looking at the trend in its profitability, Collegium Pharmaceutical's operating margin decreased by 1.1 percentage points over the last five years, but it rose by 8.4 percentage points on a two-year basis. Still, shareholders will want to see Collegium Pharmaceutical become more profitable in the future.
In Q1, Collegium Pharmaceutical generated an operating profit margin of 12.2%, down 21.9 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable.
Collegium Pharmaceutical's EPS grew at an astounding 46.4% compounded annual growth rate over the last five years, higher than its 17.3% annualized revenue growth. However, this alone doesn't tell us much about its business quality because its operating margin didn't expand.
Diving into Collegium Pharmaceutical's quality of earnings can give us a better understanding of its performance. A five-year view shows that Collegium Pharmaceutical has repurchased its stock, shrinking its share count by 6.4%. This tells us its EPS outperformed its revenue not because of increased operational efficiency but financial engineering, as buybacks boost per share earnings.
In Q1, Collegium Pharmaceutical reported EPS at $1.49, up from $1.42 in the same quarter last year. This print beat analysts' estimates by 2.8%. Over the next 12 months, Wall Street expects Collegium Pharmaceutical's full-year EPS of $6.45 to grow 11.4%.
We enjoyed seeing Collegium Pharmaceutical beat analysts' revenue expectations this quarter. We were also happy its EPS outperformed Wall Street's estimates. Overall, this print had some key positives. The stock remained flat at $27.27 immediately following the results.
Is Collegium Pharmaceutical an attractive investment opportunity right now? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
29 minutes ago
- Bloomberg
Chicago Bears Weigh Sale of McKenna's Minority Stake
The Chicago Bears are exploring a sale of the minority stake owned by the late Andrew McKenna Sr., according to people familiar with the matter. The exact size of the stake isn't known. McKenna died in 2023. The descendants of George Halas, the team's founder, own approximately 80% of the team. In addition to McKenna's stake, some shares are owned by insurance billionaire Pat Ryan, 88. Ryan and McKenna originally purchased 19.7% of the club in 1990.
Yahoo
31 minutes ago
- Yahoo
Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)
Insmed Incorporated (NASDAQ:INSM) is among the 13 Biotech Stocks with Huge Upside Potential. Kelly Shi of Jefferies has given Insmed Incorporated (NASDAQ:INSM) a buy recommendation, stating that she is confident in the TPIP treatment's impending Phase 2 data for pulmonary arterial hypertension. A biopharmaceutical research team taking notes in front of a laboratory's microscope. Shi anticipates a substantial decrease in pulmonary vascular resistance, the main outcome of the trial, of 20%, which is regarded as a definite success. If the results are encouraging, TPIP may replace Tyvaso, the current standard treatment. On June 4, Wells Fargo reaffirmed its Buy recommendation, with a price objective of $107. Shi points out that TPIP's once-daily dosage is a significant benefit over Tyvaso's four-times-daily schedule, which could increase adherence and make it more appealing to patients as well as physicians. The efficacy potential of TPIP is supported by interim study results that show additional advantages in six-minute walk distance (6MWD). Shi expects significant market penetration in light of these considerations, which could lead to an increase in Insmed Incorporated (NASDAQ:INSM)'s valuation. Both analysts highlight that if future trial results live up to predictions, TPIP has the potential to completely change the way that PAHs are treated. Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical firm that improves the lives of individuals suffering from serious and rare diseases. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Medication
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S. Court of Appeals maintained the legality of its composition of matter patent for the medication Nuplazid, which treats psychosis in Parkinson's disease. A research scientist looking through a microscope in a lab, symbolizing the biopharmaceutical company's innovative approach to medical treatments. The verdict supports ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in its legal struggle with India-based MSN Laboratories and upholds a December 2023 ruling by the U.S. District Court of Delaware. A later patent claim with the same priority date cannot be declared invalid by the court. According to CEO Catherine Owen Adams, Nuplazid's patent protection has been extended to 2030. The 34 mg capsule is also protected by a separate formulation patent that runs through 2038. The U.S. FDA authorized Nuplazid in 2016 to treat delusions and hallucinations linked to psychosis in Parkinson's disease. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)'s legal stance in a different action against Aurobindo Pharma was further strengthened by the latest decision. When taken as a whole, these results solidify the company's portfolio of intellectual property in the face of generic competition, guaranteeing prolonged market exclusivity for its flagship neurological medication. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical firm that specializes in the creation and marketing of medications that treat uncommon diseases and disorders of the central nervous system. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data